HC Wainwright & Co. Reiterates Buy on Revance Therapeutics, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a price target of $41.
September 20, 2023 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance Therapeutics has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $41.
The reiteration of a 'Buy' rating and maintenance of a $41 price target by HC Wainwright & Co. indicates a positive outlook for Revance Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100